An extended phase Ib study of epertinib, an orally active...

European Journal of Cancer 2018 / 11 Vol. 103

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours

Arkenau, H.-T., Italiano, A., Mak, G., Toulmonde, M., Baird, R.D., Garcia-Corbacho, J., Plummer, R., Flynn, M., Forster, M., Wilson, R.H., Tosi, D., Adenis, A., Donaldson, K., Posner, J., Kawabata, I.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
103
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/j.ejca.2018.07.134
Date:
November, 2018
File:
PDF, 666 KB
english, 2018
Conversion to is in progress
Conversion to is failed